Evidence map›Paper›PMID 34737227›Full record

ArticleThe European respiratory journal2022

External validation of a refined four-stratum risk assessment score from the French pulmonary hypertension registry.

Athénaïs Boucly, Jason Weatherald, Laurent Savale, Pascal de Groote, Vincent Cottin, Grégoire Prévot, Ari Chaouat, François Picard, Delphine Horeau-Langlard, Arnaud Bourdin and 8 more

Abstract read
In one paragraph

Article in The European respiratory journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
108citing papers in PubMed, 4 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

108 citing papers in PubMed, 4 syntheses or guidelines pooled it.

  1. Management of pulmonary arterial hypertension in systemic sclerosis: from classical treatments to new horizons.European respiratory review : an official journal of the European Respiratory Society · 2026
    Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Review
  13. Review
  14. Pulmonary arterial hypertension with signs of venous/capillary involvement in connective tissue diseases: paradigms and paradoxes.European respiratory review : an official journal of the European Respiratory Society · 2026
    Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Prognostic Value of the RVFWLS/PASP Ratio in Pulmonary Arterial Hypertension.Journal of cardiovascular development and disease · 2026
    Article

48 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

18 authors.

Athénaïs BouclyUniversité Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.ORCID 0000-0001-6246-5557
Jason WeatheraldUniversity of Calgary, Dept of Medicine, Division of Respirology, and Libin Cardiovascular Institute, Calgary, AB, Canada.ORCID 0000-0002-0615-4575
Laurent SavaleUniversité Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.ORCID 0000-0002-6862-8975
Pascal de GrooteUniversité de Lille, Service de Cardiologie, CHU Lille, Institut Pasteur de Lille, Inserm U1167, Lille, France.
Vincent CottinUniversité Lyon 1, INRAE, UMR754, IVPC, National Reference Centre for Rare Pulmonary Diseases, Hospices Civils de Lyon, Lyon, France.ORCID 0000-0002-5591-0955
Grégoire PrévotCHU de Toulouse, Hôpital Larrey, Service de Pneumologie, Toulouse, France.
Ari ChaouatInserm UMR_S1116, Faculté de Médecine de Nancy, Université de Lorraine, Département de Pneumologie, CHRU de Nancy, Vandoeuvre-lès-Nancy, France.ORCID 0000-0001-6056-202X
François PicardUniversité Bordeaux, Hôpital Cardiologique du Haut-Lévêque, Heart Failure Unit and Pulmonary Hypertension Expert Centre, Bordeaux, France.
Delphine Horeau-LanglardCHU de Nantes, Hôpital Laënnec, Service de Pneumologie, Nantes, France.
Arnaud BourdinUniversité Montpellier, CHU Montpellier, Dept of Respiratory Diseases, Montpellier, France.ORCID 0000-0002-4645-5209
Etienne-Marie JutantUniversité Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.ORCID 0000-0002-1374-1890
Antoine BeurnierUniversité Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.ORCID 0000-0002-0481-3266
Mitja JevnikarUniversité Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.
Xavier JaïsUniversité Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.
Gérald SimonneauUniversité Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.
David MontaniUniversité Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.ORCID 0000-0002-9358-6922
Olivier SitbonUniversité Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France.ORCID 0000-0002-1942-1951
Marc HumbertUniversité Paris-Saclay, School of Medicine, Le Kremlin-Bicêtre, France marc.humbert@aphp.fr.ORCID 0000-0003-0703-2892

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

introductionContemporary risk assessment tools categorise patients with pulmonary arterial hypertension (PAH) as low, intermediate or high risk. A minority of patients achieve low risk status with most remaining intermediate risk. Our aim was to validate a four-stratum risk assessment approach categorising patients as low, intermediate-low, intermediate-high or high risk, as proposed by the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA) investigators.

methodsWe evaluated incident patients from the French PAH Registry and applied a four-stratum risk method at baseline and at first reassessment. We applied refined cut-points for three variables: World Health Organization functional class, 6-min walk distance and N-terminal pro-brain natriuretic peptide. We used Kaplan-Meier survival analyses and Cox proportional hazards regression to assess survival according to three-stratum and four-stratum risk approaches.

resultsAt baseline (n=2879), the four-stratum approach identified four distinct risk groups and performed slightly better than a three-stratum method for predicting mortality. Four-stratum model discrimination was significantly higher than the three-stratum method when applied during follow-up and refined risk categories among subgroups with idiopathic PAH, connective tissue disease-associated PAH, congenital heart disease and portopulmonary hypertension. Using the four-stratum approach, 53% of patients changed risk category from baseline compared to 39% of patients when applying the three-stratum approach. Those who achieved or maintained a low risk status had the best survival, whereas there were more nuanced differences in survival for patients who were intermediate-low and intermediate-high risk.

conclusionsThe four-stratum risk assessment method refined risk prediction, especially within the intermediate risk category of patients, performed better at predicting survival and was more sensitive to change than the three-stratum approach.

Indexed as

Hypertension, PulmonaryPulmonary Arterial HypertensionFamilial Primary Pulmonary HypertensionHumansRegistriesRisk Assessment

Identifiers

PMID34737227
PMCPMC9245192

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.